Integrated Bioanalysis for Cell Therapy Oncology: A 360biolabs Case Study in Decision-Ready Data

When Oncology Innovation Depends on Integrated Bioanalysis

As 360biolabs marks ten years of enabling future medicines, the most useful stories are not only milestones. They are the programs that show how bioanalytical decisions shape clinical evidence.

Oncology cell therapy programs create complex analytical questions from the first clinical study. Sponsors need to understand exposure, persistence, immune response, biomarker movement and safety signals. These questions cannot be answered by one assay alone.

This case study looks at how 360biolabs supported the sponsor’s first-in-human Phase 1/2a oncology program in adults with an advanced solid tumour indication. The work required integrated PK, ADA, biomarker, immunophenotyping and molecular assay capability, supported by method transfer, qualification and quality-led execution.

The Problem: Multiple Clinical Questions, One Early-Phase Program

The sponsor, an Australian clinical-stage immunotherapy company, engaged 360biolabs to support its next-generation cell therapy program. The study required a bioanalytical approach that could address PK, safety, biomarkers, immunophenotyping and immunogenicity readiness within a single clinical framework.

For many therapeutics, pharmacokinetic assessment helps define exposure, dosing, administration route and schedule. In cell therapy, the question is more complex. The sponsor needed to quantify investigational cell therapy levels in patient samples, monitor immune-cell changes, assess biomarker signals, confirm the absence of replication-competent lentivirus and prepare for future anti-drug antibody assessment.

The challenge was not only technical. The methods also needed to be transferred or developed, qualified or validated and executed with consistency so that data could support clinical decisions and remain aligned with global regulatory expectations.

The Method: a Fit-For-Purpose, Multi-Platform Strategy

360biolabs combined PK-focused molecular measurement, immunophenotyping by flow cytometry, biomarker assays, multiplex immunoassays and ADA readiness. Each method contributed a different view of the same clinical question: how the therapy behaved in patients and how patients responded to the therapy.

Capabilities showcased in this case:

Molecular assays for PK, safety and cell-level measurement

Molecular assays are commonly used to support pharmacokinetic and pharmacodynamic assessment, particularly for newer modalities such as cell and gene therapies. 360biolabs leverages real-time PCR, quantitative PCR and digital PCR within its molecular technology suite to support clinical programs.

For this program, qPCR testing was used to confirm the absence of replication-competent lentivirus in patient samples. dPCR also supported PK assessment by quantifying investigational cell therapy levels in whole blood. This provided a molecular readout of cells in circulation.

The process was transferred using a qualified flow cytometry protocol from the prior GMP laboratory. 360biolabs subsequently qualified the workflow to support consistency, reproducibility and confidence in the generated data.

Immunophenotyping by flow cytometry to characterise cellular response

Flow cytometry provided a complementary cellular view. Immunophenotyping helped characterise patient immune-cell populations, while flow-based assessment measured investigational cell therapy levels on T cells using a target-specific ectodomain assay.

In parallel, 360biolabs conducted a comprehensive immune-cell profile of peripheral blood. The panel assessed populations, helping monitor immune-system changes throughout the study.

Biomarkers and multiplex immunoassays to add immune-response context

Cell therapy studies often require more than cell enumeration. Biomarkers of immune activation, inflammation and cytokine signalling can influence how clinical data are interpreted.

360biolabs used multiplex immunoassays to measure biomarkers including cytokines and chemokines. These readouts provided additional context on immune activity throughout the trial.

Together, the molecular, cellular, biomarker and immunological assays created a multi-dimensional assessment of safety, pharmacokinetics and immune response.

ADA readiness for future development

Immunogenicity planning was also important. All biotherapeutics have the potential to trigger an immune response, including anti-drug antibodies that bind to different epitopes on a therapeutic antigen.

Regulators expect sponsors to monitor and characterise anti-drug antibodies specific to a biotherapeutic to evaluate efficacy and safety. 360biolabs offers a complete ADA determination process, including screening, confirmatory, titre, characterisation and neutralising antibody assays.

For the sponsor, 360biolabs developed an ADA assay designed to detect anti-drug antibodies against the investigational cell therapy. The method was prepared with future validation needs in mind, supporting continuity as the program advanced.

Next-generation sequencing for deeper molecular characterisation

Next-generation sequencing can complement targeted molecular assays when a program requires sequence-level information or broader exploratory biomarker insight. For complex oncology and cell therapy studies, it may help extend the evidence strategy beyond a single analyte or single assay type.

The appropriate use of sequencing depends on the clinical question, sample type, analyte, endpoint and regulatory purpose. 360biolabs can incorporate sequencing into an integrated bioanalytical plan where it is scientifically justified.

The Result: Data That Supported The Next Decision Point

All key methods were successfully transferred and qualified. The client received high-quality, on-schedule data spanning safety, PK, biomarkers, immunophenotyping and immune monitoring.

The outcome was decision-ready bioanalytical data that helped the sponsor understand investigational cell therapy behaviour, patient immune response, biomarker signals and safety-related molecular endpoints during early clinical development.

What This Case Demonstrates for Early Oncology Programs

This program reflects a broader point for sponsors developing complex oncology therapies. Early-phase bioanalysis is not a back-end testing requirement. It is part of the clinical strategy.

Three principles stand out.

1. The assay strategy should match the clinical decision. A cell therapy program may require PK, ADA, biomarker, immunophenotyping and molecular data to interpret safety, exposure and immune response. Method selection should start with the decisions the sponsor needs to make.

2. Assay transfer and the qualification or validation process protects data continuity. When methods move between laboratories or clinical phases, the transfer process must preserve consistency. This is particularly important when a program is generating first-in-human data.

3. Immunogenicity planning should begin early. ADA and neutralising antibody strategies are most useful when considered before they become urgent. Readiness gives sponsors a clearer path into later-stage development.